Neuroscience Disease Areas

Our portfolio of unique capabilities and state-of-the-art instrumentation can support and advance your neuroscience research in various disease areas.

human nerve cell

At Charles River, we combine deep expertise and extensive capabilities to create innovative, flexible, and efficient solutions to advance neurological research and drug discovery. Our scientists continue to establish the most relevant in vitro and in vivo disease models to target acute and chronic neurological diseases. Our team is uniquely positioned to partner with clients, accelerating drug development from early discovery to the delivery of exciting new CNS therapies.

We offer disease specific models and assay systems to validate therapeutic modalities, including small molecules, biologics, and gene therapies for efficacy and safety. Our portfolio includes validated models with clinically relevant endpoints for established and emerging disease conditions.

Current therapies for Alzheimer’s disease (AD) primarily target tau and amyloid beta (Aβ) peptides and include inhibitors to reduce tau protein phosphorylation and BACE inhibitors to reduce Aβ levels. Aβ antibodies are also used to sequester free Aβ from plasma for clearance by the immune system. The development of effective AD therapies is very challenging and few compounds have shown significant benefits in clinical trials, primarily due to the lack of druggable targets and reliable biomarkers.

At Charles River, our scientists can guide you in the selection of the appropriate assay or disease model for every stage of the drug discovery process. Our extensive portfolio supports novel study designs and offers end-to-end validated in vitro services and in vivo models of pharmacology and toxicology. Our novel imaging modalities, behavioral tests and biomarker endpoint assays enable you to make effective decisions to help identify new therapies for Alzheimer’s disease.

Ask Us How We Can Support Your Program

We've included a list of our available capabilities and models below, and have answered some frequently asked questions about our Alzheimer’s disease models.

In Vitro Capabilities

In Vivo Models

Chronic and acute pain are high-interest areas for novel drug discovery. Analgesics that effectively block acute pain often do not work well for chronic pain management. Despite recent advances, many types of pain are still devoid of effective treatments. Preclinical in vivo and in vitro models are widely used to explore complex pain mechanisms as well as to screen novel therapies for pain.

At Charles River, we have developed validated models for in vitro and in vivo studies along with a comprehensive toolkit, including imaging, translational behavior and fine motor kinematics to accelerate novel therapies to treat acute and chronic pain. We offer comprehensive ion channel panels focused on pain as well as multiple in vivo readouts, including tactile and thermal hyperalgestia, cold allodynia, nocifensive behavior, fine motor kinematics, dynamic weight bearing and kinetic PET imaging.

Ask Us How We Can Support Your Program

We've included a list of our available capabilities and models below, and have answered some frequently asked questions about our pain models.

In Vitro Capabilities

In Vivo Models

There are thousands of rare diseases spanning various therapeutic areas, and many of the diseases lack therapies or even knowledge of disease drivers. Recent trends in a supportive regulatory environment and pharmaco-economic incentives are driving increased investments in rare disease drug discovery.

Charles River has developed tools for quicker and more translational preclinical studies that will help push more clinical candidates targeting rare diseases into the clinic. This includes validating relevant models and investigating the mechanisms of action using appropriate biomarker endpoints. Most importantly, given the dearth of in vitro and in vivo models that can be used to test orphan drug compounds, we are committed to making these tools available to the drug development community.

We offer end-to-end drug discovery services from target identification to IND enabling safety/toxicology studies via integrated multi-disciplinary teams across multiple therapeutic areas. Our teams use state-of-the-art capabilities and resources to customize rare and orphan disease drug discovery across several therapeutic areas.

Ask Us How We Can Support Your Program

Tools

In Vivo Models